Cardiopulmonary exercise testing is proposed to improve risk stratification for pulmonary arterial hypertension, a condition where 5-year survival remains poor at 60-65%.
Extract Despite decades of therapeutic advances, 5-year survival in pulmonary arterial hypertension (PAH) remains unacceptably poor at 60–65%, depending on subtype and cohort 1–3. A key driver is inadequate risk stratification that overlooks right ventricular (RV) maladaptation. RV afterload adaptation is the principal determinant of outcome 4, 5, yet conventional assessment tools, including transthoracic echocardiography and the 6-min walk test, provide an incomplete picture of the pathophysiology.
Constantine et al. (Fri,) conducted a editorial in pulmonary arterial hypertension. Cardiopulmonary exercise testing vs. 6-minute walk test was evaluated. Cardiopulmonary exercise testing is proposed to improve risk stratification for pulmonary arterial hypertension, a condition where 5-year survival remains poor at 60-65%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: